达嘉维康：子公司磷酸奥司他韦颗粒此轮未进入集采

Core Viewpoint - The company, Dajia Weikang, announced that its subsidiary's Oseltamivir phosphate granules did not qualify for the current centralized procurement due to a lack of two years of production experience for similar formulations [1] Group 1 - The company is actively preparing for market access and expansion efforts for Oseltamivir phosphate granules [1] - The goal is to increase coverage in grassroots markets to benefit more patients [1]